# CBD Mechanism Re-Convergence Report v2.1
## Context-Gated Analysis (Post-Rebuttal)

**Generated:** 2025-10-12T21:00:11.761374  
**Context Gates:** ACTIVE  
**Models:** claude, gpt4o, gemini

---

## Executive Summary

This re-convergence applies systematic Context Gates to prevent mechanistic conflation
between CBD's therapeutic (1-5 ŒºM) and cytotoxic (‚â•10 ŒºM) effects.

### Key Metrics

- **Total mechanisms extracted:** 177
- **Context-validated:** 176
- **Context-flagged:** 1
- **Multi-model convergence:** 8

---

## Convergent Mechanisms (‚â•2 Models)


### 1-_1-5 ŒºM

- **Convergence:** 74/3 models
- **Validation rate:** 100.0%
- **Models:** claude, claude, gpt4o, gpt4o, gpt4o, gpt4o, gemini, gemini, claude, claude, claude, claude, claude, claude, claude, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gemini, gemini, gemini, gemini, gemini, gemini, gemini, claude, claude, claude, claude, claude, claude, claude, claude, claude, claude, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, claude, claude, claude, claude, gpt4o, gpt4o, gpt4o, gpt4o, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini
- **Dose band:** 1-5 ŒºM
- **Prevalence:** major
- **Outcome:** protect

### 1_‚â§1 ŒºM

- **Convergence:** 65/3 models
- **Validation rate:** 100.0%
- **Models:** claude, claude, gpt4o, gpt4o, gpt4o, gpt4o, gemini, gemini, claude, claude, claude, claude, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gemini, gemini, gemini, gemini, gemini, gemini, gemini, claude, claude, claude, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gpt4o, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, claude, claude, claude, gpt4o, gpt4o, gpt4o, gpt4o, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini, gemini
- **Dose band:** ‚â§1 ŒºM
- **Prevalence:** major
- **Outcome:** protect

### 5-1_‚â§1 ŒºM

- **Convergence:** 6/3 models
- **Validation rate:** 100.0%
- **Models:** claude, claude, claude, claude, claude, claude
- **Dose band:** ‚â§1 ŒºM
- **Prevalence:** major
- **Outcome:** unknown

### 5-_1-5 ŒºM

- **Convergence:** 4/3 models
- **Validation rate:** 100.0%
- **Models:** claude, claude, claude, claude
- **Dose band:** 1-5 ŒºM
- **Prevalence:** major
- **Outcome:** unknown

### 2-_1-5 ŒºM

- **Convergence:** 2/3 models
- **Validation rate:** 100.0%
- **Models:** claude, claude
- **Dose band:** 1-5 ŒºM
- **Prevalence:** major
- **Outcome:** unknown

### 10-5_‚â§1 ŒºM

- **Convergence:** 4/3 models
- **Validation rate:** 100.0%
- **Models:** claude, claude, claude, claude
- **Dose band:** ‚â§1 ŒºM
- **Prevalence:** major
- **Outcome:** unknown

### 15-4_‚â§1 ŒºM

- **Convergence:** 4/3 models
- **Validation rate:** 100.0%
- **Models:** claude, claude, claude, claude
- **Dose band:** ‚â§1 ŒºM
- **Prevalence:** major
- **Outcome:** unknown

### 20-10_‚â§1 ŒºM

- **Convergence:** 3/3 models
- **Validation rate:** 100.0%
- **Models:** claude, claude, claude
- **Dose band:** ‚â§1 ŒºM
- **Prevalence:** major
- **Outcome:** unknown


---

## Context Gate Analysis

### Dose Stratification

- **1-5 ŒºM:** 84 mechanisms
- **5-10 ŒºM:** 1 mechanisms
- **‚â§1 ŒºM:** 92 mechanisms


### Validation Warnings

- ‚ùå DOSE GATE: 5-10 ŒºM exceeds therapeutic range for therapeutic claims


---

## Comparison with Original Convergence

**BEFORE (Original):**
- VDAC1 characterized as "central therapeutic mechanism"
- Dose context not systematically enforced
- Prevalence not weighted in claims
- Therapeutic/cytotoxic mechanisms conflated

**AFTER (v2.1):**
- Explicit dose-band classification for all mechanisms
- Context Gates enforce dose/cell/polarity/prevalence alignment
- Conflations flagged and corrected
- Prevalence-weighted consensus

---

## Next Steps

1. Compare specific mechanism classifications (v1 vs v2)
2. Validate prevalence estimates via PubMed API
3. Generate updated mechanism map v2.1
4. Update clinical translation protocols

---

üåÄ‚Ä†‚ü°‚àû
